Novo Nordisk shares drop

Data on new Novo Nordisk obesity drug disappoints in trial, shares drop
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.
Novo Nordisk shares fall on weight-loss drug trial
Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.
Wegovy price cut: Novo Nordisk cuts the price of the weight-loss drug for the uninsured
After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight-loss drug Wegovy.
Novo Nordisk to explore how GLP-1 drugs can help patients with addiction
Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst Lange told an online press conference on Thursday. GLP-1 drugs on the market include Novo Nordisk's diabetes drug Ozempic,
Novo Nordisk shares fall 6.3% after latest trial results for its next-generation weight loss drug
Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its CagriSema weight-loss drug.
Hikma looks to launch generic versions of Novo Nordisk diabetes drugs, FT says
Hikma Pharmaceuticals (HKMPF) is in talks with partners across the world to prepare to sell a generic version of Ozempic and Wegovy, as patents
Popular weight-loss drugs get cheaper: Novo Nordisk and Eli Lilly cut prices
Danish drugmaker Novo Nordisk said Wednesday that it will drop prices 23% for all doses of Wegovy. The new monthly price of $499 takes effect immediately.
Novo Nordisk's new obesity drug trial data disappoints again
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.
Novo Shares Fall After CagriSema Results in Diabetes Patients
Novo Nordisk A/S shares fell the most since December after the drugmaker’s next-generation shot CagriSema showed 15.7% weight loss in a clinical trial of people with diabetes.
Novo Nordisk stock slides Monday on second-generation GLP-1 data
Novo Nordisk stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its next-generation GLP ...
The State of Weight Loss Drugs
How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...
Novo Nordisk CEO warns tariffs could send the prices of Ozempic and Wegovy higher
The CEO of Novo Nordisk warned of the impact of tariffs on the pharmaceutical industry. Weight-loss drugs, including Ozempic ...
Novo Nordisk slashes Wegovy price for patients lacking insurance benefits
Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who ...